Evidence map›Paper›PMID 33474971›Full record

ArticleCirculation2021

Targeting 5-HT

J Caleb Snider, Lance A Riley, Noah T Mallory, Matthew R Bersi, Prachi Umbarkar, Rekha Gautam, Qinkun Zhang, Anita Mahadevan-Jansen, Antonis K Hatzopoulos, Luc Maroteaux and 2 more

Open access · greenAbstract read
In one paragraph

Article in Circulation, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed
7.2field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 56 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Potent and Selective Human 5-HTJournal of medicinal chemistry · 2024
    Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Structure activity relationships of 5-HTEuropean journal of medicinal chemistry · 2023
    Article
  20. Development of a Peripherally Restricted 5-HTJACC. Basic to translational science · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 3 countries.

J Caleb SniderDepartment of Biomedical Engineering, Vanderbilt University, Nashville, TN (J.C.S., L.A.R., N.T.M., M.R.B., R.G., A.M.-J., W.D.M.).
Lance A RileyDepartment of Biomedical Engineering, Vanderbilt University, Nashville, TN (J.C.S., L.A.R., N.T.M., M.R.B., R.G., A.M.-J., W.D.M.).
Noah T MalloryDepartment of Biomedical Engineering, Vanderbilt University, Nashville, TN (J.C.S., L.A.R., N.T.M., M.R.B., R.G., A.M.-J., W.D.M.).
Matthew R BersiDepartment of Biomedical Engineering, Vanderbilt University, Nashville, TN (J.C.S., L.A.R., N.T.M., M.R.B., R.G., A.M.-J., W.D.M.).
Prachi UmbarkarDivision of Cardiovascular Disease, Department of Medicine, University of Alabama at Birmingham (P.U., Q.Z., H.L.).
Rekha GautamDepartment of Biomedical Engineering, Vanderbilt University, Nashville, TN (J.C.S., L.A.R., N.T.M., M.R.B., R.G., A.M.-J., W.D.M.).
Qinkun ZhangDivision of Cardiovascular Disease, Department of Medicine, University of Alabama at Birmingham (P.U., Q.Z., H.L.).
Anita Mahadevan-JansenDepartment of Biomedical Engineering, Vanderbilt University, Nashville, TN (J.C.S., L.A.R., N.T.M., M.R.B., R.G., A.M.-J., W.D.M.).
Antonis K HatzopoulosDivision of Cardiovascular Medicine, Department of Medicine and Department of Cell and Developmental Biology, Vanderbilt University Medical Center, Nashville, TN (A.K.H.).
Luc MaroteauxInstitut National de la Sante et de la Recherche Medicale Unite Mixte de Recherche-S 1270, Paris, France (L.M.).
Hind LalDivision of Cardiovascular Disease, Department of Medicine, University of Alabama at Birmingham (P.U., Q.Z., H.L.).
W David MerrymanDepartment of Biomedical Engineering, Vanderbilt University, Nashville, TN (J.C.S., L.A.R., N.T.M., M.R.B., R.G., A.M.-J., W.D.M.).
Vanderbilt University · USUniversity of Alabama at Birmingham · USUniversité Sorbonne Nouvelle · FRVanderbilt University Medical Center · US

Funding

CLINICAL PHARMACOLOGY TRAINING PROGRAMT32GM007569 · NIGMS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Bjorn C Knollmann · 1985 to 2026
$12.4M
Training In Cardiovascular ResearchT32HL007411 · NHLBI · VANDERBILT UNIVERSITY · PI BECKMAN, JOSHUA A · 1985 to 2020
$7.2M
Mechanobiology of Cardiopulmonary FibrosisR35HL135790 · NHLBI · VANDERBILT UNIVERSITY · PI MERRYMAN, WILLIAM D · 2017 to 2023
$5.5M
Signaling Mechanisms Governing Myocardial Fibrosis in Diseased HeartR01HL133290 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Hind Lal · 2017 to 2026
$3.6M
Project-002R01HL143074 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Hind Lal · 2019 to 2026
$3.4M
Functional heterogeneity of cardiac reparative cells after injuryR01HL138519 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI HATZOPOULOS, ANTONIS · 2017 to 2020
$1.6M
Serotonergic Receptor Targeted Therapy for Degenerative Aortic Valve DiseaseR01HL115103 · NHLBI · VANDERBILT UNIVERSITY · PI MERRYMAN, WILLIAM D · 2013 to 2016
$1.5M
Targeting Cadherin-11 for the Treatment of Calcific Aortic Valve DiseaseF32HL154596 · NHLBI · VANDERBILT UNIVERSITY · PI RILEY, LANCE · 2020 to 2021
$111k
Identification of immunotherapeutic targets in cardiovascular diseaseK99HL146951 · NHLBI · VANDERBILT UNIVERSITY · PI BERSI, MATTHEW RYAN · 2019 to 2019
$99k
NHLBI NIH HHS F32 HL154596NHLBI NIH HHS K99 HL146951NHLBI NIH HHS R01 HL115103NHLBI NIH HHS R01 HL133290NHLBI NIH HHS R01 HL138519NHLBI NIH HHS R01 HL143074NHLBI NIH HHS R35 HL135790NHLBI NIH HHS T32 HL007411NIGMS NIH HHS T32 GM007569
6 · The paper itself

Abstract

backgroundMyocardial infarction (MI) induces an intense injury response that ultimately generates a collagen-dominated scar. Although required to prevent ventricular rupture, the fibrotic process is often sustained in a manner detrimental to optimal recovery. Cardiac myofibroblasts are the cells tasked with depositing and remodeling collagen and are a prime target to limit the fibrotic process after MI. Serotonin 2B receptor (5-HT

methodsWe used 2 pharmacological antagonists to explore the effect of 5-HT

results5-HT

conclusionsTogether, our findings illustrate that 5-HT

Indexed as

AnimalsFemaleFibrosisHumansMiceMice, KnockoutMyocardial InfarctionSerotonin 5-HT2 Receptor AntagonistsSignal TransductionSerotonin 5-HT2 Receptor Antagonistscardiac fibrosiscollagen remodelingmyocardial infarctionserotonin 2B receptor

Identifiers

PMID33474971
PMCPMC8009826
OpenAlexW3125179691

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.